|
 |
Pharmaceutical Manufacturing and Packing Sourcer
|
Many pharmaceutical companies operating on a global basis are worried by the Consumer Product and Safety Commission's (CPSC) enforcement (which began on 23rd November 2000) of child-resistant packaging for clinical trials packs containing a potentially hazardous amount of drug, as part of America's Poison Prevention Packaging Act (PPPA). This could have a knock-on effect for the packaging of clinical trials in Europe with the recent introduction of the EU GCP Clinical Trials Directive, signed in December 2000 and to be implemented into member states legislation within two years.
Consumer groups in Europe are campaigning for standards for child resistance compliance to be brought more in line with the US protocol.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Biovian expands - and invests in new capacity
More info >> |
|
 |
